EVarQuit. This ongoing NCI-funded randomized controlled trial not only extends our evaluation of an extinction-learning approach to improve treatment outcome but also provides tests of candidate treatment mechanisms. To accomplish the latter, all 320 participants complete two lab sessions evaluating changes in cigarette and food reinforcement and craving, 9 weeks of ecological momentary assessment (EMA), and provide repeated samples to assess the time course of medication (varenicline) levels and its role in treatment response. Collaborators include Drs Martin Mahoney, Stephen Tiffany, Craig Colder, Rachel Tyndale, Jennifer Wray, and Julie Gass. Find out more at quitforgoodwny.com. A CTSA-funded supplement to this trial is evaluating two promising reinforcement approaches for maintaining EMA adherence in the trial.
Additional active research includes multiple student-led projects, including:
- The development and evaluation of improved assessment of self-reports related to quitting (led by graduate student Sarah Tonkin).
- A laboratory evaluation of the time course of abstinence from JUUL, a pod-based electronic nicotine delivery system (led by grad student Adam Ferkin).
- A double-blind, placebo controlled examination of the effects of acute caffeine on sustained attention in adolescents (led by grad student Bobby Cooper; in collaboration with Dr. Jennifer Temple).
- A preliminary evaluation of the effects of varenicline on cigarette and food reinforcement in treatment-seeking smokers (led by grad student Schuyler Lawson; in collaboration with the EVarQuit Team).
The lab also has recent/ongoing/proposed studies related to the following:
- Multiple aspects of reinforcement, cognition, and creativity in ADHD (with Dr. Greg Fabiano et al.).
- Studies of habituation of reinforcer effectiveness (with Dr. Jerry Richards).
- The world’s first randomized controlled trials to enhance collaboration among early career scholars (funded by NCATS; see http://www.buffalo.edu/innovationlabs.html; collaborators include Drs. Tim Murphy and Katherine Hartmann).